Skip to main content

Table 4 Comparison of subjects with and without colistin-resistant E. coli or K. pneumoniae colonization after study enrollment among subjects without colonization with colistin-resistant E. coli or K. pneumoniae at study enrollment

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables Colonization after enrollment (n = 42) No Colonization after enrollment (n = 73) p-value
Female gender (yrs), n (%) 20 (47.6%) 37 (50.7%) 0.75
Age (yrs), mean ± SD 66.6 ± 15.6 68.5 ± 15.1 0.54
ICU admission, n (%) 15 (35.7%) 24 (32.9%) 0.76
Previous hospitalization, n (%) 21 (50.0%) 37 (50.7%) 0.94
APACHE II score at study enrollment, mean ± SD 21.8 ± 7.2 21.9 ± 7.6 0.92
Mechanical ventilation, n (%) 39 (92.9%) 58 (79.5%) 0.06
Indwelling central venous catheter, n (%) 28 (66.7%) 40 (54.8%) 0.21
Surgery, n (%) 26 (61.9%) 39 (53.4%) 0.38
Chronic intermittent hemodialysis, n (%) 4 (9.5%) 10 (13.7%) 0.51
Antibiotic use for current hospitalization prior to study enrollment and during study period, n (%)
 Carbapenems 35 (83.3%) 66 (90.4%) 0.26
 Cephalosporins 20 (47.6%) 31 (42.5%) 0.59
 Beta-lactam/beta-lactamase inhibitors 33 (78.6%) 52 (71.2%) 0.39
 Fluoroquinolones 25 (59.5%) 33 (45.2%) 0.14
 Vancomycin 23 (54.8%) 38 (52.1%) 0.78
 Aminoglycosides 5 (11.9%) 2 (2.7%) 0.10
Antibiotic use for the current hospitalization after study enrollment, n (%)
 Carbapenems 19 (45.2%) 34 (46.6%) 0.89
 Cephalosporins 6 (14.3%) 4 (5.5%) 0.17
 Beta-lactam/beta-lactamase inhibitors 25 (59.5%) 36 (49.3%) 0.29
 Fluoroquinolones 19 (45.2%) 25 (34.2%) 0.24
 Vancomycin 17 (40.5%) 27 (37.0%) 0.71
 Aminoglycosides 4 (9.5%) 2 (2.7%) 0.19
Colistin use within 3 months prior to study enrollment, n (%) 9 (21.4%) 2 (2.7%) 0.002
Total amount of colistin (mg), median (range) 2800 (400–9350) 2000 (300–10,650) 0.03
Total duration of colistin use (days), median (range) 13 (2–55) 9 (1–32) 0.03
Total courses of colistin therapy, mean ± SD 1.3 ± 0.6 1.1 ± 0.34 0.02
Total courses of colistin therapy, range 1–3 1–3  
Patients who received more than 1 course of colistin therapy, n (%) 10 (23.8%) 6 (8.2%) 0.02
Length of hospital stay (days), median (range) 46.5 (12–246) 32 (6–192) 0.04
All-cause mortality at hospital discharge, n (%) 35 (47.9%) 19 (45.2%) 0.78